Cell Therapy · global
How Can CAR-T Manufacturing Without Viral Vectors Be Automated? Cellares and GenomeFrontier Partner to Test the Process
Taiwanese cell therapy company GenomeFrontier will evaluate transferring the GF-CART01 manufacturing process to the Cell Shuttle platform, starting with gene transfection, to explore manufacturing approaches that support U.S. clinical development and future scale-up.
Turning patients’ own immune cells into cancer treatments presents challenges not only in how to engineer the cells, but also in whether they can be manufactured consistently. Manufacturing autologous CAR-T therapies involves multiple steps, and manual operations and batch variability can make supply more challenging. A new collaboration between Cellares and Taiwanese cell therapy company GenomeFrontier Therapeutics will test whether a CAR-T manufacturing process that does not use viral vectors can be transferred to an automated platform.
The two companies announced on September 16, 2026, that they would evaluate manufacturing the investigational therapy GF-CART01 on Cellares’ Cell Shuttle platform. According to Cellares’ announcement, this is its first development collaboration with an Asian cell therapy developer, and its purpose is to support GenomeFrontier’s U.S. clinical program. What the companies have announced so far is a process transfer and automation evaluation; they have not announced that GF-CART01 has completed the transfer or that the platform has begun supplying it for clinical use.
The technical focus of the collaboration is “transfection,” the step in which genetic material is delivered into cells. The companies will test whether Cell Shuttle’s integrated electroporation equipment can accommodate GenomeFrontier’s nonviral process. Electroporation uses electrical pulses to temporarily increase cell membrane permeability, allowing nucleic acids to enter cells. Here, “virus-free” means that gene delivery does not rely on viral vectors; it does not mean that the therapy has been proven safer or more effective.
GF-CART01 is an autologous, dual-target CAR-T therapy candidate that uses patients’ own T cells and is being developed for B-cell malignancies. Diseases listed in reporting by *Genetic Engineering & Biotechnology News* include diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma. The dual-target design is intended to address problems such as tumors evading immune recognition, but the design’s intended purpose and its actual clinical benefit still need to be considered separately.
According to the collaboration announcement and related reporting, GenomeFrontier said it had obtained promising clinical data in Taiwan and was recruiting participants for a Phase 1 trial in the United States at the time of the announcement. However, this news did not provide the number of participants in the Taiwan trial, numerical efficacy results, follow-up duration, or complete safety results. It therefore does not establish the magnitude of GF-CART01’s efficacy, nor does it support an inference that a product manufactured through automation has already shown the same performance.
*Pharma Manufacturing* noted that the evaluation will also cover manufacturing consistency, scalability, and the preservation of the operational flexibility required for the nonviral process. Whether these goals can be achieved will require actual manufacturing data. For GF-CART01, the announcement did not disclose cell quality, batch success rates, manufacturing time, or cost comparisons for the automated process. Reducing costs and improving patient access to treatment remain goals the collaboration hopes to achieve.
This collaboration brings the next question to the manufacturing floor: can a cell engineering workflow with its own distinct characteristics maintain the required quality in automated equipment and expand supply as clinical development progresses? The answer will depend on subsequent process validation; whether GF-CART01 can deliver lasting benefits to patients must still be answered by clinical trials.